Anti-C1q antibodies are a promising marker for the diagnosis and management of lupus nephritis. Immunological tests can differentiate proliferative from non-proliferative lupus nephritis ...

In November 2024, the American College of Rheumatology (ACR) released a summary of their new guidelines for the screening, treatment, and management of lupus nephritis. What is important for a patient ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Twelve years is a long time by most measures, but in a field has rapidly changing as lupus nephritis research, it may as well be an eternity. “The ACR last published a lupus nephritis clinical ...

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition ...

Understanding the pathophysiology of IgA nephropathy ... such as IgA nephropathy and lupus nephritis. The Phase IIb ORIGIN clinical trial of atacicept in IgA nephropathy achieved its primary endpoint, ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Understanding the pathogenesis and pathophysiology of a disease enables ... damage include anti-dsDNA ANAs (associated with lupus nephritis [LN]), antichromatin and antichromatin ANAs (also ...

Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical ... the role of belimumab in specific settings (lupus ...

The Belimumab International Systemic Lupus Erythematosus–Lupus Nephritis (BLISS-LN ... whether any of these changes might implicate particular pathways involved in the pathophysiology of LN.

The Kidney Disease: Improving Global Outcomes (KDIGO) program has published a 2024 clinical practice guideline for the management of lupus nephritis (LN) in Kidney International and its supplements.

Here, we aimed to compare the clinical effects of mycophenolate mofetil combined with either tacrolimus or with cyclophosphamide on lupus nephritis (LN) and to analyze their influence on the ...